Skip to content
lsd.com
Unknown statusPhase 2

Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter

NCT02717052 · Medical University of Vienna

Closed to entry
Status
Not accepting participants
Phase 2
Phase
74
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The study at hand is the first to investigate ketamine's SERT binding in humans, by utilizing the highly selective SERT radioligand \[11C\]DASB and positron emission tomography.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Pilot Study II: (S)-ketamine SERT occupancy assessed with DASB binding potential (BP)

    Measured over during PET/during 135 minutes of infusion

  • Pilot Study II: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)

    Measured over during PET/during 135 minutes of infusion

  • Main Study: (S)-ketamine SERT occupancy assessed with DASB binding potential (BP)

    Measured over during PET/starting 10 minutes afer 40 minutes of infusion

  • Pilot Study I: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)

    Measured over during PET/starting 10 minutes afer 40 minutes of infusion

  • Pilot Study III: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)

    Measured over during PET

  • Pilot Study III: resting state MRI

    Measured over after PET 2

  • Pilot Study III: MRS

    Measured over after PET 2

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 55 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * 18-55 years * somatic health * severe unipolar depression according to DSM-IV (SCID) und HAM-D (for patients) * capable of giving informed consent * negative pregnancy test (females) Exclusion Criteria: * severe somatic illness * psychiatric disorder (for healthy controls) * an axis I comorbidity other than MDD , other than anxiety symptoms (for patients) * clinically relevant alterations in blood draw, ecg, and somatic testing * substance dependency disorder * intake of psychopharmacological medication in last 6 months * first degree relative with Axis 1 disorder (for Pilot I study)

Where

1 study site

FacilityCityRegionCountry
Department of Psychiatry and Psychotherapy, Medical University of ViennaVienna—Austria

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02717052 on ClinicalTrials.gov →

Last updated in the registry 2018-10-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Indication

All 7 trials from Medical University of Vienna →